BR112023002248A2 - Inibidores de quinase e usos dos mesmos - Google Patents

Inibidores de quinase e usos dos mesmos

Info

Publication number
BR112023002248A2
BR112023002248A2 BR112023002248A BR112023002248A BR112023002248A2 BR 112023002248 A2 BR112023002248 A2 BR 112023002248A2 BR 112023002248 A BR112023002248 A BR 112023002248A BR 112023002248 A BR112023002248 A BR 112023002248A BR 112023002248 A2 BR112023002248 A2 BR 112023002248A2
Authority
BR
Brazil
Prior art keywords
compounds
methods
kinase
kinase inhibitors
compositions
Prior art date
Application number
BR112023002248A
Other languages
English (en)
Inventor
Chen Chen
Original Assignee
Abm Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abm Therapeutics Corp filed Critical Abm Therapeutics Corp
Publication of BR112023002248A2 publication Critical patent/BR112023002248A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

NIBIDORES DE QUINASE E USOS DOS MESMOS. São fornecidos compostos cíclicos de iminopiridimdina e seus derivados bicíclicos, composições farmacêuticas compreendendo tais compostos, e métodos de uso de tais compostos ou composições, tais como métodos de tratamento de um distúrbio de proliferação, tal como um câncer ou um tumor, ou em algumas modalidades doenças ou distúrbios relacionados com a desregulação de quinase, tal como, mas não limitada às quinases, tais como MAPK, PDGFR, Src, PAKs, c-Kit, EphA2, EphB4, FGFR, Axl, e c-Met.
BR112023002248A 2020-08-07 2021-08-06 Inibidores de quinase e usos dos mesmos BR112023002248A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063063113P 2020-08-07 2020-08-07
PCT/US2021/044907 WO2022032071A1 (en) 2020-08-07 2021-08-06 Kinase inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
BR112023002248A2 true BR112023002248A2 (pt) 2023-03-07

Family

ID=77711412

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023002248A BR112023002248A2 (pt) 2020-08-07 2021-08-06 Inibidores de quinase e usos dos mesmos

Country Status (10)

Country Link
US (1) US20230303570A1 (pt)
EP (1) EP4192582A1 (pt)
JP (1) JP2023538521A (pt)
KR (1) KR20230112605A (pt)
CN (1) CN116710453A (pt)
AU (1) AU2021321536A1 (pt)
BR (1) BR112023002248A2 (pt)
CA (1) CA3179671A1 (pt)
MX (1) MX2023001312A (pt)
WO (1) WO2022032071A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024044713A1 (en) * 2022-08-25 2024-02-29 Enliven Inc. Naphthyridine compounds for inhibition of raf kinases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003082871A1 (en) * 2002-04-03 2003-10-09 F. Hoffmann-La Roche Ag Imidazo fused compounds
EP2348020A1 (en) 2009-12-23 2011-07-27 Esteve Química, S.A. Preparation process of erlotinib
FR2974088A1 (fr) * 2011-04-12 2012-10-19 Pf Medicament Composes pyrazolo[3,4-b]pyridines tri- et tetracycliques comme agent anticancereux
RU2019102647A (ru) * 2016-07-01 2020-08-03 Г1 Терапьютикс, Инк. Антипролиферационные средства на основе пиримидина
CA3076202A1 (en) * 2017-09-20 2019-03-28 Abm Therapeutics Corporation Cyclic iminopyrimidine derivatives as kinase inhibitors
CN110950867A (zh) * 2018-09-27 2020-04-03 首药控股(北京)有限公司 一种fgfr4激酶抑制剂及其制备方法和用途

Also Published As

Publication number Publication date
AU2021321536A1 (en) 2023-03-09
CA3179671A1 (en) 2022-02-10
CN116710453A (zh) 2023-09-05
WO2022032071A1 (en) 2022-02-10
MX2023001312A (es) 2023-04-12
KR20230112605A (ko) 2023-07-27
JP2023538521A (ja) 2023-09-08
US20230303570A1 (en) 2023-09-28
EP4192582A1 (en) 2023-06-14

Similar Documents

Publication Publication Date Title
DOP2022000077A (es) Aminas bicíclicas como inhibidoras de la cdk2
EA202190137A1 (ru) Нафтиридиноновые соединения для применения в качестве активаторов t-клеток
TN2015000355A1 (fr) Derives de pyrrolo [2, 3-d] pyrimidine servant d'inhibiteurs de kinases de type janus (jak)
EA201492176A1 (ru) Селективные ингибиторы pi3k дельта
EA201391682A1 (ru) Замещенные производные индазола, активные в качестве ингибиторов киназы
BR112018071097A2 (pt) compostos heterocíclicos como inibidores de ret cinase
BR112018077015A2 (pt) derivados de ácido borônico e usos terapêuticos dos mesmos
BR112015014701B8 (pt) Derivados de benzimidazol e seus usos
BR112017005531A2 (pt) derivados de diaril ureia como inibidores de quinase p38
BR112019024830A2 (pt) inibidores de bcl6 derivados de benzimidazolona
MY187555A (en) 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
CL2016001604A1 (es) “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
EA201890650A1 (ru) ПРОИЗВОДНЫЕ 8-[6-[3-(АМИНО)ПРОПОКСИ]-3-ПИРИДИЛ]-1-ИЗОПРОПИЛ-ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА В КАЧЕСТВЕ СЕЛЕКТИВНЫХ МОДУЛЯТОРОВ КИНАЗЫ МУТАЦИИ АТАКСИИ-ТЕЛЕАНГИЭКТАЗИИ (ATM) ДЛЯ ЛЕЧЕНИЯ РАКА
EA201691151A1 (ru) Соединения для лечения пациентов с ros1-мутантными раковыми клетками
UA113156C2 (xx) Циклобутилзаміщені похідні піролопіридину й піролопіримідину як інгібітори jak
BR112018002465A2 (pt) derivados de heteroarila como inibidores de parp
BR112012020693A2 (pt) derivados de ciclobutano e metilciclobutano como inibidores de janus quinase
BR112019005969A2 (pt) inibidores seletivos de jak1 inovadores e usos dos mesmos
BR112015015653A2 (pt) derivados de azaindol como inibidores de quinases de proteínas
ATE534292T1 (de) Spiroverbindungen und anwendungsverfahren dafür
EA202192093A1 (ru) Пиразолопиридины и триазолопиридины в качестве ингибиторов a2а/a2b
BR112019001439A8 (pt) compostos e composições e usos dos mesmos
CO2022018806A2 (es) Inhibidores de las cinasas receptoras del receptor del factor de crecimiento de fibroblastos
BR112023002248A2 (pt) Inibidores de quinase e usos dos mesmos